文献类型：期刊文献

英文题名：Gastric Cancer Organoids: Mechanistic Insights, Drug Discovery, and Translational Advances in Precision Medicine

作者：Liu, Na[1];Zhang, Yan[1];Liu, Yao[1];Dong, Xiao[1];Li, Yu[1];Geng, Jinrui[1];Li, Yonghong[1,2,3]

第一作者：Liu, Na

通信作者：Li, YH[1];Li, YH[2]

机构：[1]Gansu Univ Chinese Med, Lanzhou, Peoples R China;[2]Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumor, 204 Donggang West Rd, Lanzhou 730000, Peoples R China;[3]Gansu Prov Hosp, Inst Clin Res & Translat Med, 204 Donggang West Rd, Lanzhou 730000, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumor, 204 Donggang West Rd, Lanzhou 730000, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Inst Clin Res & Translat Med, 204 Donggang West Rd, Lanzhou 730000, Peoples R China.

年份：2026

卷号：26

期号：3

起止页码：345

外文期刊名：JOURNAL OF GASTRIC CANCER

收录：;Scopus(收录号：2-s2.0-105044223556);WOS:【SCI-EXPANDED(收录号:WOS:001824929100005)】；

基金：Funding This work was supported by the National Natural Science Foundation (grant No. 82160534) , Central Government Guided Fund for Local Science and Technology Development (grant No. 25ZYJA003) , and Gansu Province Major Science and Technology Innovation Project in the Health Sector (grant No. GSWSZD2024-01) . Additional funding was provided by the Natural Science Foundation of Gansu Province (grant No. 23JRRA1491) and Gansu Provincial Health Industry Project (grant No. GSMSQN2021-004) .

语种：英文

外文关键词：Gastric cancer; Organoids; Precision medicine; Drug screening

摘要：Significant advances in the treatment of localized gastric cancer have been achieved through early screening, improved diagnostic techniques, surgeries, and adjuvant chemotherapy; however, the need for personalized treatment remains under debate. This review highlights the use of gastric cancer organoid (GCO) models to study cancer mechanisms, drug discovery, and precision medicine, focusing on their ability to simulate the tumor microenvironment, reveal cell heterogeneity, and assess drug responses. In particular, the integration of CRISPR/Cas9 gene editing with GCOs provides a powerful platforms for identifying new drug targets and supporting clinical applications in precision medicine. This review also explores the potential of these organoids in future research, particularly in optimizing treatment strategies and developing personalized therapies, thus offering new directions for precision treatment of gastric cancer.